Duchenne Muscular Dystrophy

Upcoming events – Fibrogen and Alnylam look to broaden their horizons
Upcoming events – Fibrogen and Alnylam look to broaden their horizons
EP Vantage
FibroGen
roxadustat
pamrevlumab
Duchenne Muscular Dystrophy
givosiran
Alnylam
Flag link:
CRISPR corrects DMD in mice for a year in Sarepta-supported study
CRISPR corrects DMD in mice for a year in Sarepta-supported study
Fierce Biotech
Duke University
Sarepta Therapeutics
CRISPR
gene editing
DMD
Duchenne Muscular Dystrophy
Flag link:
Solid Bio is hit by another setback as initial biopsies spotlight a flop for Duchenne MD
Solid Bio is hit by another setback as initial biopsies spotlight a flop for Duchenne MD
Endpoints
Solid Biosciences
clinical trials
Duchenne Muscular Dystrophy
SGT-001
Flag link:
Suvodirsen For Duchenne Muscular Dystrophy Selected for FDA Complex Innovative Trial Designs Pilot Program
Suvodirsen For Duchenne Muscular Dystrophy Selected for FDA Complex Innovative Trial Designs Pilot Program
CP Wire
suvodirsen
Wave Life Sciences
Duchenne Muscular Dystrophy
muscular dystrophy
Flag link:
Suvodirsen For Duchenne Muscular Dystrophy Selected for FDA Complex Innovative Trial Designs Pilot Program
suvodirsen
Wave Life Sciences
Duchenne Muscular Dystrophy
muscular dystrophy
Flag link:
15 For ’19: Key Clinical Data To Watch For Next Year (Part 1)
15 For ’19: Key Clinical Data To Watch For Next Year (Part 1)
Xconomy
clinical trials
Alzheimer's disease
Biogen
Duchenne Muscular Dystrophy
Pfizer
Solid Biosciences
Sarepta Therapeutics
hemophilia A
Biomarin
Multiple Myeloma
Celgene
Bluebird Bio
Amgen
solid tumors
Bristol-Myers Squibb
Nektar Therapeutics
age-related macular degeneration
Regenxbio
SAGE Therapeutics
MorphoSys
Flag link:
Increase collaboration to widen access to DMD drugs, trials and care
Increase collaboration to widen access to DMD drugs, trials and care
Pharmaforum
Duchenne Muscular Dystrophy
clinical trials
Flag link:
Sarepta Gene Therapy Appears To Help Fourth Boy With Duchenne Muscular Dystrophy
Sarepta Gene Therapy Appears To Help Fourth Boy With Duchenne Muscular Dystrophy
Forbes
Sarepta Therapeutics
Duchenne Muscular Dystrophy
gene therapy
Flag link:
Catabasis Pharmaceuticals Initiates Ph III Trial for Promising Duchenne Muscular Dystrophy Drug
Catabasis Pharmaceuticals Initiates Ph III Trial for Promising Duchenne Muscular Dystrophy Drug
CP Wire
Catabasis
edasalonexent
Duchenne Muscular Dystrophy
Flag link:
Catabasis Pharmaceuticals Initiates Ph III Trial for Promising Duchenne Muscular Dystrophy Drug
Catabasis
edasalonexent
Duchenne Muscular Dystrophy
Flag link:
FDA lifts clinical hold on Sarepta's Duchenne MD gene therapy, clearing the way to a quick launch of a pivotal trial
FDA lifts clinical hold on Sarepta's Duchenne MD gene therapy, clearing the way to a quick launch of a pivotal trial
Endpoints
Sarepta Therapeutics
FDA
gene therapy
Duchenne Muscular Dystrophy
clinical trials
Flag link:
Europe Advisory Panel Rejects Sarepta’s Duchenne Drug Once Again
Europe Advisory Panel Rejects Sarepta’s Duchenne Drug Once Again
Xconomy
Europe
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 51
eteplirsen
Flag link:
Researchers Use CRISPR to Treat Duchenne Muscular Dystrophy in Dogs
Researchers Use CRISPR to Treat Duchenne Muscular Dystrophy in Dogs
BioSpace
DMD
Duchenne Muscular Dystrophy
CRISPR
drug development
Flag link:
Pfizer Ends Trials for Domagrozumab in Drug for Duchenne Muscular Dystrophy
Pfizer Ends Trials for Domagrozumab in Drug for Duchenne Muscular Dystrophy
CP Wire
Pfizer
domagrozumab
Duchenne Muscular Dystrophy
Flag link:
Pfizer Ends Trials for Domagrozumab in Drug for Duchenne Muscular Dystrophy
Pfizer
domagrozumab
Duchenne Muscular Dystrophy
Flag link:
Mallinckrodt Starts Phase II Duchenne Muscular Dystrophy Study but Will They Meet Recruitment Targets?
Mallinckrodt Starts Phase II Duchenne Muscular Dystrophy Study but Will They Meet Recruitment Targets?
Xtalks
Mallinckrodt
MNK-1411
Duchenne Muscular Dystrophy
clinical trials
Flag link:
FDA slaps a hold on Sarepta’s Duchenne MD study in the wake of stellar early results
FDA slaps a hold on Sarepta’s Duchenne MD study in the wake of stellar early results
Endpoints
Sarepta Therapeutics
Duchenne Muscular Dystrophy
FDA
clinical hold
gene therapy
Flag link:
Catabasis Plans Ph III Trial for Edasalonexent in Duchenne Muscular Dystrophy
Catabasis Plans Ph III Trial for Edasalonexent in Duchenne Muscular Dystrophy
CP Wire
edasalonexent
clinical trials
Duchenne Muscular Dystrophy
Flag link:
Catabasis Plans Ph III Trial for Edasalonexent in Duchenne Muscular Dystrophy
Catabasis
edasalonexent
Duchenne Muscular Dystrophy
Flag link:
Summit Therapeutics Ditches Duchenne Drug In Wake of Phase 2 Failure
Summit Therapeutics Ditches Duchenne Drug In Wake of Phase 2 Failure
Xconomy
Summit Therapeutics
ezutromid
clinical trials
Duchenne Muscular Dystrophy
Flag link:

Pages